New focus on treatment for rheumatoid arthritis
Although the pathogenesis of rheumatoid arthritis increasingly continues to be well understood, therapeutic approaches to the disease remain relatively unsophisticated and based more on anecdote than scientific reasoning. During the past year, additional supportive data regarding the usefulness of f...
Gespeichert in:
| Veröffentlicht in: | Current opinion in rheumatology 1993-03, Vol.5 (2), p.178-183 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 183 |
|---|---|
| container_issue | 2 |
| container_start_page | 178 |
| container_title | Current opinion in rheumatology |
| container_volume | 5 |
| creator | Trentham, David E |
| description | Although the pathogenesis of rheumatoid arthritis increasingly continues to be well understood, therapeutic approaches to the disease remain relatively unsophisticated and based more on anecdote than scientific reasoning. During the past year, additional supportive data regarding the usefulness of front-line agents such as methotrexate and hydroxychloroquine were acquired, and novel potential interventions, such as pulse gammaglobulin and OM-8980 were identified. Animal model studies still support the prospect that genuine remission-inducing strategies will be realized in the future.Current Opinion in Rheumatology 1993, 5:178-183 |
| doi_str_mv | 10.1097/00002281-199305020-00009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_75638963</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75638963</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2709-d2fd1bce487fcb5dbaeb9392f93f4bcd1c20671130608b721309dadd6ea5e4993</originalsourceid><addsrcrecordid>eNp1UUtPwzAMjhBojMFPQOqJW5mT9JEc0cRLmuAC5yhNXLXQriNJVfHvydjYDV9sfX589mdCEgq3FGS5hGiMCZpSKTnkwCDdQfKEzGnOaVrIgp_GGDJIRUnpObnw_gOAMknZjMxElrOyEHOyfMEpqQcz-mTYJMGhDj1uQoRc4hocex2G1ibahca1ofWX5KzWncerg1-Q94f7t9VTun59fF7drVPDSpCpZbWllcFMlLWpcltprCSXrJa8zipjqWFQxL04FCCqksVAWm1tgTrHLN60IDf7uVs3fI3og-pbb7Dr9AaH0asyL7iIR8ZCsS80bvDeYa22ru21-1YU1E4r9aeVOmr1C-04rg8cY9WjPTYexIn5bJ-fhi6g85_dOKFTDeouNOq_F_Af6bZzkw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75638963</pqid></control><display><type>article</type><title>New focus on treatment for rheumatoid arthritis</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Trentham, David E</creator><creatorcontrib>Trentham, David E</creatorcontrib><description>Although the pathogenesis of rheumatoid arthritis increasingly continues to be well understood, therapeutic approaches to the disease remain relatively unsophisticated and based more on anecdote than scientific reasoning. During the past year, additional supportive data regarding the usefulness of front-line agents such as methotrexate and hydroxychloroquine were acquired, and novel potential interventions, such as pulse gammaglobulin and OM-8980 were identified. Animal model studies still support the prospect that genuine remission-inducing strategies will be realized in the future.Current Opinion in Rheumatology 1993, 5:178-183</description><identifier>ISSN: 1040-8711</identifier><identifier>EISSN: 1531-6963</identifier><identifier>DOI: 10.1097/00002281-199305020-00009</identifier><identifier>PMID: 8452768</identifier><language>eng</language><publisher>United States: Lippincott-Raven Publishers</publisher><subject>Animals ; Anti-Bacterial Agents - therapeutic use ; Arthritis, Rheumatoid - drug therapy ; Dogs ; Humans ; Hydroxychloroquine - therapeutic use ; Methotrexate - therapeutic use ; Rats</subject><ispartof>Current opinion in rheumatology, 1993-03, Vol.5 (2), p.178-183</ispartof><rights>Lippincott-Raven Publishers.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2709-d2fd1bce487fcb5dbaeb9392f93f4bcd1c20671130608b721309dadd6ea5e4993</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8452768$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Trentham, David E</creatorcontrib><title>New focus on treatment for rheumatoid arthritis</title><title>Current opinion in rheumatology</title><addtitle>Curr Opin Rheumatol</addtitle><description>Although the pathogenesis of rheumatoid arthritis increasingly continues to be well understood, therapeutic approaches to the disease remain relatively unsophisticated and based more on anecdote than scientific reasoning. During the past year, additional supportive data regarding the usefulness of front-line agents such as methotrexate and hydroxychloroquine were acquired, and novel potential interventions, such as pulse gammaglobulin and OM-8980 were identified. Animal model studies still support the prospect that genuine remission-inducing strategies will be realized in the future.Current Opinion in Rheumatology 1993, 5:178-183</description><subject>Animals</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Dogs</subject><subject>Humans</subject><subject>Hydroxychloroquine - therapeutic use</subject><subject>Methotrexate - therapeutic use</subject><subject>Rats</subject><issn>1040-8711</issn><issn>1531-6963</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1UUtPwzAMjhBojMFPQOqJW5mT9JEc0cRLmuAC5yhNXLXQriNJVfHvydjYDV9sfX589mdCEgq3FGS5hGiMCZpSKTnkwCDdQfKEzGnOaVrIgp_GGDJIRUnpObnw_gOAMknZjMxElrOyEHOyfMEpqQcz-mTYJMGhDj1uQoRc4hocex2G1ibahca1ofWX5KzWncerg1-Q94f7t9VTun59fF7drVPDSpCpZbWllcFMlLWpcltprCSXrJa8zipjqWFQxL04FCCqksVAWm1tgTrHLN60IDf7uVs3fI3og-pbb7Dr9AaH0asyL7iIR8ZCsS80bvDeYa22ru21-1YU1E4r9aeVOmr1C-04rg8cY9WjPTYexIn5bJ-fhi6g85_dOKFTDeouNOq_F_Af6bZzkw</recordid><startdate>199303</startdate><enddate>199303</enddate><creator>Trentham, David E</creator><general>Lippincott-Raven Publishers</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199303</creationdate><title>New focus on treatment for rheumatoid arthritis</title><author>Trentham, David E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2709-d2fd1bce487fcb5dbaeb9392f93f4bcd1c20671130608b721309dadd6ea5e4993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Animals</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Dogs</topic><topic>Humans</topic><topic>Hydroxychloroquine - therapeutic use</topic><topic>Methotrexate - therapeutic use</topic><topic>Rats</topic><toplevel>online_resources</toplevel><creatorcontrib>Trentham, David E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current opinion in rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Trentham, David E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New focus on treatment for rheumatoid arthritis</atitle><jtitle>Current opinion in rheumatology</jtitle><addtitle>Curr Opin Rheumatol</addtitle><date>1993-03</date><risdate>1993</risdate><volume>5</volume><issue>2</issue><spage>178</spage><epage>183</epage><pages>178-183</pages><issn>1040-8711</issn><eissn>1531-6963</eissn><abstract>Although the pathogenesis of rheumatoid arthritis increasingly continues to be well understood, therapeutic approaches to the disease remain relatively unsophisticated and based more on anecdote than scientific reasoning. During the past year, additional supportive data regarding the usefulness of front-line agents such as methotrexate and hydroxychloroquine were acquired, and novel potential interventions, such as pulse gammaglobulin and OM-8980 were identified. Animal model studies still support the prospect that genuine remission-inducing strategies will be realized in the future.Current Opinion in Rheumatology 1993, 5:178-183</abstract><cop>United States</cop><pub>Lippincott-Raven Publishers</pub><pmid>8452768</pmid><doi>10.1097/00002281-199305020-00009</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1040-8711 |
| ispartof | Current opinion in rheumatology, 1993-03, Vol.5 (2), p.178-183 |
| issn | 1040-8711 1531-6963 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_75638963 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Animals Anti-Bacterial Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Dogs Humans Hydroxychloroquine - therapeutic use Methotrexate - therapeutic use Rats |
| title | New focus on treatment for rheumatoid arthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T20%3A14%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20focus%20on%20treatment%20for%20rheumatoid%20arthritis&rft.jtitle=Current%20opinion%20in%20rheumatology&rft.au=Trentham,%20David%20E&rft.date=1993-03&rft.volume=5&rft.issue=2&rft.spage=178&rft.epage=183&rft.pages=178-183&rft.issn=1040-8711&rft.eissn=1531-6963&rft_id=info:doi/10.1097/00002281-199305020-00009&rft_dat=%3Cproquest_cross%3E75638963%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75638963&rft_id=info:pmid/8452768&rfr_iscdi=true |